BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript

Core Viewpoint - The discussion focuses on addressing acute agitation associated with schizophrenia and bipolar disorders, emphasizing the need for patient-centered innovations in non-clinical settings [1][3]. Group 1: Company Mission and Commitment - BioXcel Therapeutics aims to transform patient care by advancing solutions that alleviate the burden of acute agitation on patients, caregivers, and the healthcare system [3]. - The company recognizes the significant challenges posed by episodes of acute agitation, particularly outside clinical environments, highlighting the urgency for practical innovations [3]. Group 2: Event Structure and Participants - The event features a roundtable discussion moderated by Anjalee Khemlani, an award-winning journalist known for her in-depth reporting on healthcare [2]. - The participation of clinical experts is intended to provide valuable insights into the management of agitation in real-world settings [2].